Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2022-08-26 Director's Dealing
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics ASA - Mandatory notification for close associate of primary insider
Director's Dealing Classification · 100% confidence The document text details a transaction involving shares of Nykode Therapeutics ASA. Specifically, it outlines the 'Details of the person discharging managerial responsibilities/person closely associated' (Radforsk Investeringstiftelse), the 'Reason for the notification' (Closely associated party of Anders Tuv, board member), and the 'Details of the transaction,' which is a 'Pledge of shares' involving 9,000,000 shares. This structure—reporting personal share transactions by directors or closely associated parties—is characteristic of insider trading disclosures, which fall under the 'Director's Dealing' category.
2022-08-26 English
Nykode Therapeutics ASA - Mandatory notification for close associate of primary insider
Major Shareholding Notification Classification · 99% confidence The document is very short (698 characters) and explicitly states that further information is available 'in the attached'. The content concerns a mandatory notification regarding a pledge of shares by a close associate of a primary insider, referencing Article 19 of the EU Market Abuse Regulation. This type of insider transaction disclosure, when presented as a brief announcement pointing to an attachment, is best classified as a general Regulatory Filing (RNS), as there is no specific code for 'Insider Transaction Notification' that fits better, and it is not a Director's Dealing (DIRS) which typically reports the executive's own trade, nor is it a Major Shareholding Notification (MRQ) which focuses on ownership thresholds. Given the brevity and the reference to an attachment, the 'MENU VS MEAL' rule suggests classifying it as an announcement rather than the detailed report itself. RNS is the most appropriate fallback.
2022-08-26 English
Nykode Therapeutics - Quarterly report 2Q 2022
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'INTERIM REPORT' and covers the '2nd Quarter 2022'. It contains detailed financial tables (Key financial figures), management commentary, and comprehensive updates on R&D activities, which confirms it is a substantive financial report for a period shorter than a full fiscal year, rather than just an announcement or a summary. Q2 2022
2022-08-24 English
Nykode Therapeutics - Quarterly report 2Q 2022
Report Publication Announcement Classification · 95% confidence The document is a short announcement (under 3,000 characters) that states the financial results for the second quarter of 2022 have been announced and provides a link to where the actual financial report can be found. Per the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself, making it a Report Publication Announcement (RPA). H1 2022
2022-08-24 English
Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022
Report Publication Announcement Classification · 99% confidence The document is a short announcement (3169 characters) explicitly stating that Nykode Therapeutics 'will report its financial results for the first half of 2022 on August 24, 2022' and will host a webcast presentation. It does not contain the actual financial results or the comprehensive report itself. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report will be published or is attached classifies as a Report Publication Announcement (RPA).
2022-08-22 English
Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022
Report Publication Announcement Classification · 99% confidence The document is a short announcement dated August 22, 2022, stating that Nykode Therapeutics 'will report its financial results for the first half of 2022 on August 24, 2022' and will host a webcast presentation. This is not the actual financial report (which would be an IR or ER), but rather an announcement about the *timing* of the report release and associated presentation. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report fits the definition of a Report Publication Announcement (RPA).
2022-08-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.